Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageWe are a clinical-stage biotechnology company focused on unlocking the broad potential of ribonucleic acid (“RNA”) medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. Our RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Wave Life Sciences Ltd. (WVE) reported revenue of $38M in Q1 2026 (quarter ended March 31, 2026), up 317% from the same quarter a year earlier. That came with net loss of $26M. For the full year FY2025, revenue was $43M (−61% year on year) and net income −$204M.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.